P1.13-06 First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small Cell Lung Cancer
暂无分享,去创建一个
A. Shaw | B. Solomon | J. Martini | C. Baik | T. Bauer | A. Polli | Y. Goto | M. Carpentieri | T. Takahashi